Reference no: EM133505696
Case Study: The paper will follow a particular disease state Rheumatoid arthritis and product oral drug baricitinib, over the course of its development from pre-clinical to clinical, and post-market.
Using the guidance "Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products Guidance for Industry", use the template/required sections for a pre-NDA meeting and make a pre-NDA meeting request and package.
Remember the questions from the pre-IND meeting and agreements made. Incorporate into the pre-NDA as appropriate:
Background: Provide an overview of the development history of baricitinib for rheumatoid arthritis.
Clinical/regulatory
Question 1: What are the recommended primary and secondary endpoints for the Phase 3 trial?
Question 2: Are there any specific safety monitoring requirements during the trial?
Question 3: What are the expectations for the IND submission content and format?
Clinical/safety
Question 4: Are there any safety concerns or precautions that should be considered during the trial?
Clinical pharmacology
Question 5: What pharmacokinetic and pharmacodynamic data are required for the IND submission?
Question 6: Are there any special considerations for drug-drug interactions?
Nonclinical
Question 7: What nonclinical data should be included in the IND submission?